BETH FRETTIM: Open Payments
NPI 1851923205 · JOHNSTON, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,055 in 115 payments from 18 companies in 2025. Trend: 2023 $1,537 · 2024 $2,068 · 2025 $2,055
Food & beverage: $2,047Education: $8
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 26 | $410 |
| Vanda Pharmaceuticals Inc. | 12 | $344 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $230 |
| ABBVIE INC. | 14 | $198 |
| E.R. Squibb & Sons, L.L.C. | 11 | $159 |
| Janssen Pharmaceuticals, Inc | 10 | $138 |
| MDD US Operations, LLC | 7 | $110 |
| Axsome Therapeutics, Inc. | 4 | $104 |
| Lundbeck LLC | 4 | $77 |
| Corium, LLC | 3 | $76 |
Products named: REXULTI, FANAPT, CAPLYTA, VRAYLAR, COBENFY, SPRAVATO, Qelbree, Auvelity.
Industry payments across IA — which companies pay providers there.
